Overview of the role of macrophage migration inhibitory factor (MIF) in inflammatory bowel disease

Current Pharmaceutical Design

Volumn 15, Issue 18, 2009, Pages 2104-2109

  Nishihira, Jun ^a   Mitsuyama, Keiichi ^b  

^a HOKKAIDO INFORMATION UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

1,3 glucan; Chemokine; Crohn's disease; Cytokine; Dextran sulfate sodium; Inflammatory bowel disease; Macrophage migration inhibitory factor; Ulcerative colitis

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GASTROINTESTINAL AGENT; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2; MACROPHAGE MIGRATION INHIBITION FACTOR; MACROPHAGE MIGRATION INHIBITION FACTOR ANTIBODY; MACROPHAGE MIGRATION INHIBITION FACTOR SCHIZOPHYLLAN COMPLEX; MESSENGER RNA; UNCLASSIFIED DRUG;

COLITIS; COLON CANCER; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENTERITIS; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; HEPATITIS; HUMAN; INNATE IMMUNITY; NONHUMAN; PANCREATITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; DNA, ANTISENSE; GASTROINTESTINAL NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER DISEASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; PANCREATITIS; STOMACH ULCER;

EID: 68449098789     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788489113     Document Type: Review

References (75)

1. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966; 153: 80-2.
2. David JR. Delayed hypersensitivity in vitro: Its mediation bycell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 1966; 56: 72-7.
3. Bucala R. MIF re-discovered: Pituitary hormone and glucocorticoid-induced regulator of cytokine production. FASEB J 1996; 7: 19-24.
4. Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994; 179: 1895-902.
5. Bacher M, Meinhardt A, Lan HY, Mu W, Metz CN, Chesney JA, et al. Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol 1997; 150: 235-46.
6. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993; 365: 756-9.
7. Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996; 93: 7849-54.
8. Nishihira J. Macrophage migration inhibitory factor (MIF): Its essential role in the immune system and cell growth. J Interferon Cytokine Res 2000; 20: 751-62.
9. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 1999; 189: 341-6.
10. Donnelly SC, Haslett C, Reid PT, Grant IS, Wallace WA, Metz CN, et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 1997; 3: 320-3.
11. Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M, Nishihira J. Macrophage migration inhibitory factor upregulates expression of matrix metaloproteinases in synovial fibroblasts of rheumatoid arthritis. J Biol Chem 2000; 275: 444-50.
12. Weiser WY, Temple PA, Witek-Giannotti JS, Remold HG, Clark SC, David JR. Molecular cloning of a cDNA encding a human macrophage migration inhibitory factor. Proc Natl Acad Sci USA 1989; 86: 7522-6.
13. Paralkar V, Wistow G. Cloning the human gene for macrophage migration inhibitory factor (MIF). Genomics 1994; 19: 48-51.
14. Nishihira J, Kuriyama T, Nishino H, Ishibashi T, Sakai M, Nishi S. Purification and characterization of human macrophage migration inhibitory factor: Evidence for specific binding to glutathione and formation of subunit structure. Biochem Mol Biol Int 1993; 31: 841-50.
15. Nishihira J. Novel pathophysiological aspects of macrophage migration inhibitory factor. Int J Mol Med 1998; 2: 17-28.
16. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995; 377: 68-71.
17. Meinhardt A, Bacher M, McFarlane JR, Metz CN, Seitz J, Hedger MP, et al. Macrophage migration inhibitory factor production by Leydig cells: Evidence for a role in the regulation of testicular function. Endocrinology 1996; 137: 5090-5.
18. Calandra T, Bernhagen C, Bizzari C, Sergi R, Caselli G, Kleemann R, et al. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994; 179: 1985-92.
19. Onodera S, Suzuki K, Matsuno T, Kaneda K, Takagi M, Nishihira J. Macrophage migration inhibitory factor induces phagocytosis of foreign particles by macrophages in autocrine and paracrine fashion. Immunology 1997; 92: 131-7
20. Abe R, Peng T, Sailors J, Bucala R, Metz CN. Regulation of the CTL response by macrophage migration inhibitory factor. J Immunol 2001; 166: 747-53.
21. Waeber G, Calandra T, Roduit R, Haefliger JA, Bonny C, Thompson NJ, et al. Insulin secretion is regulated by the glucosedependent production of islet beta cell macrophage migration inhibitory factor. Proc Natl Acad Sci USA 1997; 94: 4782-7.
22. Santos L, Hall P, Metz C, Bucala R, Morand EF. Role of macrophage migration inhibitory factor (MIF) in murine antigeninduced arthritis: interaction with glucocorticoids. Clin Exp Immunol 2001; 123: 309-14.
23. Daun JM, Cannon JG. Macrophage migration inhibitory factor antagonizes hydrocortisone-induced increase in cytosolic IkBα. Am J Physiol 2000; 279: R1043-9.
24. Masser C, Eckmann L, Paesold G, Kim HS, Kagnoff MF. Ubiquitous production of macrophage migration inhibitory factor by human gastric and intestinal epiethelium. Gastroenterology 2002; 122: 667-80.
25. O'Keeffe J, Lynch S, Whelan A, Jackson J, Kennedy NP, Weir DG, et al. Flow cytometric measurement of intracellular migration inhibition factor and tumour necrosis factor alpha in the mucosa of patients with coeliac disease. Clin Exp Immunol 2001; 125: 376-82.
26. Ohkawara T, Nishihira J, Takeda H, Hige S, Kato M, Sugiyama T, et al. Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology 2002; 123: 256-70.
27. Ohkawara T, Miyashita K, Nishihira J, Mitsuyama K, Takeda H, Kato M, et al. Transgenic overexpression of macrophage migration inhibitory factor renders mice markedly more susceptible to experimental colitis. Clin Exp Immunol 2005; 140: 241-8.
28. Ohkawara T, Nishihira J, Ishiguro Y, Otsubo E, Nagai K, Takeda H, et al. Resistance to experimental colitis depends on cytoprotective heat shock proteins in macrophage migration inhibitory factor null mice. Immunol Lett 2006; 107: 148-54.
29. Murakami H, Akbar AM, Matsui H, Onji M. Macrphage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: Clinical implications and pathogenic significance. Eur J Clin Invest 2001; 31: 337-43.
30. Murakami H, Akbar SM, Matsui H, Horiike N, Onji M. Macrophage migration inhibitory factor activates antigen-presenting dendric cells and induces inflammatory cytokines in ulcerative colitis. Clin Exp Immunol 2002; 128: 504-10.
31. de Jong YP, Abadia-Molina AC, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA, et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2001; 2: 1061-6.
32. Tarlton JF, Whiting CV, Tunmore D, Bregenholt S, Reimann J, Claesson MH, et al. The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenisis of a murine model of colitis. Am J Pathol 2000; 157: 1927-35.
33. von Lampe B, Barthel B, Coupland SE, Riechen EO, Rosewicz S. Differential expression of matrix metalloproteases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000; 47: 12-4.
34. Matsuno K, Adachi Y, Yamamoto H, Goto A, Arimura Y, Endo T, et al. The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis. J Gastroenterol 2003; 38: 348-54.
35. Wiercinska-Drapalo A, Jaroszewicz J, Flisiak R, Prokopowicz D. Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity. World J Gastroenterol 2003; 9: 2843-5.
36. Ohkawara T, Mitsuyama K, Takeda H, Asaka M, Fujiyama Y, Nishihira J. Lack of macrophage migration inhibitory factor suppresses innate immune response in murine dexran sulfate sodium-induced colitis. Scand J Gastroenterol 2008; 43: 1497-504.
37. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994; 107: 1643-52.
38. Banks C, Bateman A, Payne R, Johnson P, Sheron N. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 2003; 199: 28-35.
39. Gijsbers K, Van Assche G, Joossens S, Struyf S, Proost P, Rutgeerts P, et al. CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP/CXCL6 expression in inflamed intestinal tissue. Eur J Immunol 2004; 34: 1992-2000.
40. Reinecker HC, Loh EY, Ringer DJ, Mehta A, Rombeau JL, MacDermott RP, et al. Monocyte-chemoattractant protein 1 gene expression in intestinal epithelial cells and inflammatory bowel disease mucosa. Gastroenterology 1995; 108: 40-50.
41. MacDermott RP, Sanderson IR, Reinecker HC. The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 1998; 4: 54-67.
42. McCormack G, Moriarty D, O'Donoghue DP, McCormick PA, Sheahan K, Baird AW. Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res 2001; 50: 491-5.
43. Uguccioni M, Gionchetti P, Robbiani DF, Rizzello F, Peruzzo S, Campieri M, et al. Increased expression of IP-10, IL-8, MCP-1, MCP-3 in ulcerative colitis. Am J Pathol 1999; 155: 331-6.
44. Sasaki S, Yoneyama H, Suzuki K, Suriki H, Aiba T, Watanabe S, et al. Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival. Eur J Immunol 2002; 32: 3197-205.
45. / mice. J Immunol 2003; 171: 1401-6.
46. Ohtsuka Y, Sanderson IR. Dextran sulfate sodium-induced inflammation is enhanced by intestinal epithelial cell chemokine expression in mice. Pediatr Res 2003; 53: 143-7.
47. + lymphocyte-associated Th-2-type immune response in the intestine. J Immunol 2000; 164: 6303-12.
48. Onodera S, Nishihira J, Koyama Y, Majima T, Aoki Y, Ichiyama H, et al. Macrophage migration inhibitory factor up-regulates the expression of interleukin-8 messenger RNA in synovial fibroblasts of rheumatoid arthritis patients: Common transcriptional regulatory mechanism between interleukin-8 and interleukin-1beta. Arthritis Rheum 2004; 50: 1437-47
49. Ichiyama H, Onodera S, Nishihira J, Ishibashi T, Nakayama T, Minami A, et al. Inhibition of joint inflammation and destruction induced by anti-type II collagen antibody/lipopolysaccharide (LPS)-induced arthritis in mice due to deletion of macrophage migration inhibitory factor (MIF). Cytokine 2004; 26: 187-94.
50. Tanino Y, Makita H, Miyamoto K, Betsuyaku T, Ohtsuka Y, Nishihira J, et al. Role of macrophage migration inhibitory factor in bleomycin-induced lung injury and fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2002; 283: L156-62.
51. Kumagi T, Akbar F, Horiike N, Onji M. Increased serum levels of macrophage migration inhibitory factor in alcoholic liver diseases and their expression in liver tissues. Clin Biochem 2001; 34: 189-93. Erratum in: Clin Biochem 2001; 34: 517.
52. Hori Y, Sato S, Yamate J, Kurasaki M, Nishihira J, Hosokawa T, et al. Immunohistochemical study of macrophage migration inhibitory factor in rat liver fibrosis induced by thioacetamide. Eur J Histochem 2003; 47: 317-24.
53. Johansson U, Olsson A, Gabrielsson S, Nilsson B, Korsgren O. Inflammatory mediators expressed in human islets of Langerhans: implications for islet transplantation. Biochem Biophys Res Commun 2003; 308: 474-9.
54. Ohkawara T, Nishihira J, Takeda H, Asaka M, Sugiyama T. Pathophysiological roles of macrophage migration inhibitory factor in gastrointestinal, hepatic, and pancreatic disorders. J Gastroenterol 2005; 40: 117-22
55. Huang XR, Chun Hui CW, Chen YX, Wong BC, Fung PC, Metz C, et al. Macrophage migration inhibitory factor is an important mediator in the pathogenesis of gastric inflammation in rats. Gastroenterology 2001; 121: 619-30.
56. Xia HH, Lam SK, Huang XR, Wong WM, Leung SY, Yuen ST, et al. Helicobacter pylori infection is associated with increased expression of macrophage migratory inhibitory factor by epithelial cells, T cells, and macrophages in gastric mucosa. J Infect Dis 2004 15; 190: 293-302.
57. Kobayashi S, Nishihira J, Watanabe S, Todo S. Prevention of lethal acute hepatic failure by antimacrophage migration inhibitory factor antibody in mice treated with bacille Calmette-Guerin and lipopolysaccharide. Hepatology 1999; 29: 1752-9.
58. Akbar SM, Abe M, Murakami H, Tanimoto K, Kumagi T, Yamashita Y, et al. Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis. Cancer Lett 2001; 171: 125-32.
59. Zhang W, Yue B, Wang GQ, Lu SL. Serum and ascites levels of macrophage migration inhibitory factor, TNF-alpha and IL-6 in patients with chronic virus hepatitis B and hepatitis cirrhosis. Hepatobiliary Pancreat Dis Int 2002; 1: 577-80.
60. Ren Y, Tsui HT, Poon RT, Ng IO, Li Z, Chen Y, et al. Macrophage migration inhibitory factor: Roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer 2003; 107: 22-9.
61. Sakai Y, Masamune A, Satoh A, Nishihira J, Yamagiwa T, Shimosegawa T. Macrophage migration inhibitory factor is a critical mediator of severe acute pancreatitis. Gastroenterology 2003; 124: 725-36.
62. Takahashi N, Nishihira J, Sato Y, Kondo M, Ogawa H, Ohshima T, et al. Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med 1998; 4: 707-14.
63. Ogawa H, Nishihira J, Sato Y, Kondo M, Takahashi N, Oshima T, et al. An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. Cytokine 2000; 12: 309-14.
64. Xia HH, Zhang ST, Lam SK, Lin MC, Kung HF, Wong BC, et al. Expression of macrophage migration inhibitory factor in esophageal squamous cell carcinoma and effects of bile acids and NSAIDs. Carcinogenesis 2005; 26: 11-5.
65. Orita K, Mannami T, Yumura M, Hayashi S, Miwa H. Change of macrophage migration inhibitory factor: Possible indicator for postoperative prognosis. Jpn J Surg 1977; 7: 118-22.
66. Shkolnik T, Livni E, Reshef R, Lachter J, Eidelman S. The macrophage migration inhibition (MIF) assay as a marker of colorectal cancer. Studies in patients with colorectal cancer, noncolonic neoplasms, and conditions predisposing to colorectal cancer. Dis Colon Rectum 1987; 30: 101-5.
67. Shkolnik T, Livni E, Reshef R, Lachter J, Eidelman S. Comparison of two lymphokines (macrophage migration inhibition, leukocyte adherence inhibition factors) and carcinoembryonic antigen, in colorectal cancer and colonic premalignant lesions. Am J Gastroenterol 1987; 82: 1275-8.
68. Reshef R, Livni E, Lachter J, Suprun H, Eidelman S, Shkolnik T. Colon cancer bearing rats produce a lymphokine which induces macrophage migration inhibition (MIF) in vitro. Comp Immunol Microbiol Infect Dis 1988; 11: 61-9.
69. Legendre H, Decaestecker C, Nagy N, Hendlisz A, Schuring MP, Salmon I, et al. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol 2003; 16: 491-504.
70. Iwaki T, Sugimura M, Nishihira J, Matsuura T, Kobayashi T, Kanayama N. Recombinant adenovirus vector bearing antisense macrophage migration inhibitory factor cDNA prevents acute lipopolysaccharide-induced liver failure in mice. Lab Invest 2003; 83: 561-70.
71. Donn RP, Shelley E, Ollier WE, Thompson W. A novel 5' - flanking region of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2001; 44: 1782-5.
72. Nohara H, Okayama N, Inoue N, Koike Y, Fujimura K, Suehiro Y, et al. Association of the -173G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol 2004; 39: 242-6.
73. Adachi Y, Yoshio-Hoshino N, Nishimoto N. The blockade of IL-6 signaling in rational drug design. Curr Pharm Des 2008; 14(12): 1217-24.
74. Bansal AT, Barnes MR. Genomics in drug discovery: The best things come to those who wait. Curr Opin Drug Discov Devel 2008; 11(3): 303-11.
75. Motilva V, Talero E, Calvo JR, Villegas I, Alarcon-de-la-Lastra C, Sanchez-Fidalgo S. Intestinal immunomodulation. Role of regulative peptides and promising pharmacological activities. Curr Pharm Des 2008; 14(1): 71-95.